Riskpilot← Back to searchSign inGet full accessIvermed Konsult AB
ABActiveOrg 5568743271Fogdegatan 2 CBusiness and other management consultancy activities · NACE 7020Est. 20110 employees
Revenue 2024
SEK 0
EBITDA margin
—
-103% vs 2023
Equity ratio
100.3%
Financial strength
Net profit 2024
SEK 199K
+300% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -8K | -103% |
| Net profit | SEK 199K | +300% |
| Total assets | SEK 2,9M | -3% |
| Equity | SEK 2,9M | +0% |
| Employees | 0 | — |
Legal name
Ivermed Konsult AB
Org number
5568743271
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
2 december 2011
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget ska bedriva konsultverksamhet av hälso- och sjukvård inom företagshälsovård, skolhälsovård och allmänmedicin, föreläsningar samt handel med finansiella instrument och förvaltning av fastigheter och skog.
Address
Fogdegatan 2 C
Email
mats.ivermark@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 437 | 65 | 345 | 272 | 0 |
| Staff expenses | — | — | — | −0 | −0 |
| EBITDA | 399 | 46 | 282 | 259 | −8 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | 399 | 46 | 282 | 259 | −8 |
| Net financials | 30 | 269 | 302 | −358 | 207 |
| Profit before tax | 430 | 315 | 584 | −100 | 199 |
| Tax | −92 | −17 | −63 | — | — |
| Net profit | 338 | 298 | 521 | −100 | 199 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 835 | 2 858 | 3 312 | 2 982 | 2 881 |
| Equity | 2 735 | 2 843 | 3 178 | 2 889 | 2 889 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 100 | 15 | 134 | 93 | −8 |
| Total debt | 100 | 15 | 134 | 93 | −8 |
EBITDA margin
-820300.0%
This company
15.8%
Market median
-5191872% vs market
20202024
Equity ratio
100.3%
This company
38.2%
Market median
+163% vs market
20202024
Return on equity
6.9%
This company
18.4%
Market median
-63% vs market
20202024
Net profit margin
19883200.0%
This company
8.1%
Market median
+245471505% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
-0.00×
This company
0.62×
Market median
+100% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Ivermed Konsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mats Werner Ivermark | Board of Directors | 0 companies |
| Mattias Erik Anders Ivermark | Deputy Board Member | 0 companies |